Co-Delivery of Itraconazole and Docetaxel by Core/Shell Lipid Nanocells for Systemic Antiangiogenesis and Tumor Growth Inhibition
Abstract
evaluations showed that the dual drug loaded DTX/ITZ-LNCs retained the cytotoxic efficacy of the DTX against both the sensitive and multidrug resistant breast cancer cell line MCF-7. DTX/ITZ-LNCs also effectively inhibited the vascular endothelial growth factor (VEGF) induced migratory and invasive actions of HUVECs and neovascularization of subcutaneously implanted matrigel plugs. The tumor growth of MCF-7 tumor xenograft model was effectively inhibited by the systemic administration of the DTX/ITZ-LNCs. Taken together, these results showed that the DTX/ITZ-LNCs provided a drug delivery platform that can optimize the combinatory effects of the antiangiogenic agent with a conventional chemotherapeutic agent.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ITZ synergy with docetaxel has been inferred against prostate and MCF-7 drug-resistant breast cancer cells.
“Regarding hedgehog signaling pathway, its synergy with docetaxel has been inferred against prostate and MCF-7 drug-resistant-breast cancer cells, though prior mechanisms has been also stated.85,94,95”
From Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights (2026) · cites this paper as [95]
Cited by
Sorted by citations
Marzi, M., Ghasemian, A., Ghanbariasad, A., Nournia, E., & Zarenezhad, E. (2026) · RSC Advances · doi:10.1039/d5ra09799a
- Authors
- Okeke, C. I., Eltahan, A. S., Zhang, T., Chen, J., Wang, Y., Xu, M.-Q., Liu, L., Yang, A.-Q., Guo, W., & Liang, X.-J.
- ORCID
- Venue
- Journal of Biomedical Nanotechnology
- Publisher
- American Scientific Publishers
- Published
- 2017-11-01
- Volume
- 13
- Issue
- 11
- Pages
- 1398-1412
- ISSN
- 1550-7033 (ISSN-L)
- OpenAlex
- W2894119902
- Cited by
- 10
- References
- 0
- Citations by year
- 2026: 2 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 3 · 2018: 1
- FWCI
- 0.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Biomedical Nanotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- itraconazole, docetaxel, dual drug delivery, angiogenesis inhibition, tumor growth inhibition, breast cancer, multidrug resistance, MCF-7 cells, vascular endothelial growth factor, endothelial cell migration and invasion, neovascularization, tumor xenografts, combination chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
